Trial Profile
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 May 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Neoantigen DNA vaccine AstraZeneca/Washington University School of Medicine (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions
- 25 Apr 2024 Planned number of patients changed from 27 to 20.
- 14 Jul 2023 Planned End Date changed from 30 Jun 2026 to 31 Mar 2030.
- 14 Jul 2023 Planned primary completion date changed from 30 Jun 2024 to 31 Mar 2028.